Mylan Launches First HIV-Combo in India

Aug 08, 2017

Street Insider

Mylan has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral drug Avonza, a treatment recommended by WHO as an alternative first-line regimen for people treated for HIV/AIDS.

Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets.

According to Mylan President Rajiv Malik, Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. Additionally, Mylan is the first to offer this combination in India.

Read the Street Insider coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments